Research Staff

Dr. Murphy is an engineer and scientist by training, earning a PhD in biomedical engineering from Rice University with focus on biomaterials for orthopedic tissue engineering and drug delivery. His postdoctoral research was sponsored by DARPA and US DoD to create regenerative medicine solutions for battlefield injuries with intent to save limbs and limit infections. He previously served as Director of R&D and Product Development for Celling Biosciences and as an independent consultant in the autologous biologics sector. He has authored 25 peer-reviewed publications in the field with nearly 3000 citations of his work. His other professional stops include NASA, ICU Medical (formerly Pfizer), and Cardinal Health. He joined Regenexx full-time in 2023 to contribute to its legacy as a leader and pioneer in orthobiologics.

Originally from St. Louis, Missouri, Dr. Dodson completed her Bachelor’s degree in Psychology from Butler University. Dr. Dodson worked in the Sleep Medicine field for several years, both on the clinical side and conducting research before receiving her Doctorate from Saint Louis University in Experimental Psychology. Following a fellowship at Northwestern University, she taught psychology at St. Louis Community College before moving to Boulder, CO.

Deciding to return to her research interests, Dr. Dodson turned to the young and growing field of regenerative medicine and joined the Regenexx Research and Development team in 2016. As the Clinical Research Director, she is responsible for all of the clinical trials conducted in partnership with the Centeno-Schultz Clinic.

Originally from the mountains of Colorado, Dustin developed a passion for science at an early age. He received his bachelor’s degree in molecular, cellular, and developmental biology from the University of Colorado, Boulder in 2008. Eager to learn more, Dustin pursed graduate studies in Biomedical Engineering at Colorado State University. In 2011, he received his masters of science from CSU, where he investigated the osteogenic potential of mesenchymal stem cells in response to bone-inducing growth factors and substrate nanotopography. For several years thereafter, Dustin remained active in stem cell research, developing and validating in vitro liver models based on human induced pluripotent stem cells for use in functional studies and toxicity screening. Dustin joined the Interventional Orthopedics Foundation as a research scientist in the summer of 2015, investigating current interventional orthopedic treatment options and educating physicians on their use and then made the transition to the Regenexx R&D team in January, 2017.